Literature DB >> 12495055

Protection of chickens after live and inactivated virus vaccination against challenge with nephropathogenic infectious bronchitis virus PA/Wolgemuth/98.

B S Ladman1, C R Pope, A F Ziegler, T Swieczkowski, C J M Callahan, S Davison, J Gelb.   

Abstract

Protection provided by live and inactivated virus vaccination against challenge with the virulent nephropathogenic infectious bronchitis virus (NIBV) strain PA/Wolgemuth/98 was assessed. Vaccinations with combinations of live attenuated strains Massachusetts (Mass) + Connecticut (Conn) or Mass + Arkansas (Ark) were given by eyedrop to 2-wk-old specific-pathogen-free leghorn chickens. After live infectious bronchitis virus (IBV) vaccination, some chickens at 6 wk of age received an injection of either an oil emulsion vaccine containing inactivated IBV strains Mass + Ark or an autogenous vaccine prepared from NIBV PA/Wolgemuth/98. Challenge with PA/Wolgemuth/98 was given via eyedrop at 10 wk of age. Serum IBV enzyme-linked immunosorbent assay antibody geometric mean titers (GMTs) after vaccination with the combinations of live attenuated strains were low, ranging from 184 to 1,354, prior to NIBV challenge at 10 wk of age. Both inactivated vaccines induced an anamnestic response of similar magnitudes with serum GMTs of 6,232-12,241. Assessment of protection following NIBV challenge was based on several criteria virus reisolation from trachea and kidney and renal microscopic pathology and IBV-specific antigen immunohistochemistry (IHC). Live attenuated virus vaccination alone with combinations of strains Mass + Conn or Mass + Ark did not protect the respiratory tract and kidney of chickens after PA/Wolgemuth/98 challenge. Chickens given a live combination vaccination of Mass + Conn and boosted with an inactivated Mass + Ark vaccine were also susceptible to NIBV challenge on the basis of virus isolation from trachea and kidney butshowed protection on the basis of renal microscopic pathology and IHC. Live IBV-primed chickens vaccinated with an autogenous inactivated PA/Wolgemuth/98 vaccine had the highest protection against homologous virulent NIBV challenge on the basis of virus isolation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495055     DOI: 10.1637/0005-2086(2002)046[0938:POCALA]2.0.CO;2

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  21 in total

1.  S1 gene sequence analysis of a nephropathogenic strain of avian infectious bronchitis virus in Egypt.

Authors:  Ahmed S Abdel-Moneim; Magdy F El-Kady; Brian S Ladman; Jack Gelb
Journal:  Virol J       Date:  2006-09-20       Impact factor: 4.099

Review 2.  [Severe acute respiratory syndrome epidemics: the end or a hiatus of the epidemic?].

Authors:  Angela Domínguez; Francesc Gudiol; Tomás Pumarola; Lluís Salleras
Journal:  Med Clin (Barc)       Date:  2003-09-20       Impact factor: 1.725

3.  Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus.

Authors:  Boyd Yount; Kristopher M Curtis; Elizabeth A Fritz; Lisa E Hensley; Peter B Jahrling; Erik Prentice; Mark R Denison; Thomas W Geisbert; Ralph S Baric
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

4.  Expression and immunoreactivity of a recombinant multi-epitope antigen designed based on four major structural proteins of avian infectious bronchitis virus.

Authors:  Qing Liu; Jin Li; Run-Li Li; Ye-Ting Ma; Peng-Lai Zhou; Wen-Wei Gao; Hai-Li Ma
Journal:  3 Biotech       Date:  2020-02-04       Impact factor: 2.406

Review 5.  Molecular mechanisms of severe acute respiratory syndrome (SARS).

Authors:  David A Groneberg; Rolf Hilgenfeld; Peter Zabel
Journal:  Respir Res       Date:  2005-01-20

Review 6.  Progress and challenges toward the development of vaccines against avian infectious bronchitis.

Authors:  Faruku Bande; Siti Suri Arshad; Mohd Hair Bejo; Hassan Moeini; Abdul Rahman Omar
Journal:  J Immunol Res       Date:  2015-04-14       Impact factor: 4.818

7.  Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by a Recombinant Baculovirus Co-Expressing S1 and N Proteins.

Authors:  Yuan Yuan; Zhi-Peng Zhang; Yi-Ning He; Wen-Sheng Fan; Zhi-Hua Dong; Li-Hua Zhang; Xin-Kuan Sun; Li-Li Song; Tian-Chao Wei; Mei-Lan Mo; Ping Wei
Journal:  Viruses       Date:  2018-06-27       Impact factor: 5.048

8.  Comparative Protective Efficacies of Novel Avian Paramyxovirus-Vectored Vaccines against Virulent Infectious Bronchitis Virus in Chickens.

Authors:  Edris Shirvani; Siba K Samal
Journal:  Viruses       Date:  2020-06-28       Impact factor: 5.048

9.  In vitro inhibition of transmissible gastroenteritis coronavirus replication in swine testicular cells by short hairpin RNAs targeting the ORF 7 gene.

Authors:  Lei He; Yan-ming Zhang; Ling-juan Dong; Min Cheng; Jing Wang; Qing-hai Tang; Gang Wang
Journal:  Virol J       Date:  2012-08-28       Impact factor: 4.099

10.  Antiviral activity of quercetin 7-rhamnoside against porcine epidemic diarrhea virus.

Authors:  Hwa-Jung Choi; Jin-Hee Kim; Choong-Hwan Lee; Young-Joon Ahn; Jae-Hyoung Song; Seung-Hwa Baek; Dur-Han Kwon
Journal:  Antiviral Res       Date:  2008-11-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.